Screener
TG Therapeutics TGTX Change In Fair Value Of Notes Payable
Change In Fair Value Of Notes Payable at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept tgtx:ChangeInFairValueOfNotesPayable.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
FAQ
- What is TG Therapeutics's change in fair value of notes payable?
- TG Therapeutics (TGTX) reported change in fair value of notes payable of -$524K in Q2 2026.
- What is the long-term trend for TG Therapeutics's change in fair value of notes payable?
- Over 2 years (2021 to 2024), TG Therapeutics's change in fair value of notes payable has grown at a -27.5% compound annual growth rate (CAGR), from $578K to -$304K.
- What does change in fair value of notes payable mean?
- Represents the non-cash adjustment to the carrying value of debt obligations measured at fair value. This reflects changes in market conditions or credit risk that impact the valuation of outstanding notes payable.
Ask your AI about TG Therapeutics's change in fair value of notes payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude